Trial data showed the new vaccine, developed by GlaxoSmithKline, was 82% effective at preventing lower respiratory tract illness caused by RSV.
USA TODAY, Courier-Post
Wed, 05/03/2023 - 10:59am
Trial data showed the new vaccine, developed by GlaxoSmithKline, was 82% effective at preventing lower respiratory tract illness caused by RSV.